Browse News
Filter News
Found 183 articles
-
Gritstone to Participate in H.C. Wainwright Global Investment Conference
5/17/2022
Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022.
-
Neoantigens Market - Business Opportunities and Growth Challenges Report
5/12/2022
Albany NY, United States: The global neoantigens market is expected to expand at a healthy rate from 2021 to 2031.
-
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
5/6/2022
Gritstone bio, Inc. reported financial results for the first quarter ended March 31, 2022 and reviewed business highlights.
-
Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Gritstone bio, Inc., a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, reported financial results for the first quarter ended March 31, 2022 and reviewed business highlights.
-
Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
5/2/2022
Gritstone bio, Inc. announced that it will report its financial results for the first quarter ended March 31, 2022 and provide recent clinical and corporate updates via a press release on Thursday, May 5, 2022 at 4:05pm Eastern Time.
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 27, 2022
4/27/2022
Gritstone bio, Inc. announced that the company’s Board of Directors has granted nine employees nonqualified stock options to purchase an aggregate of 42,550 shares of its common stock with an exercise price of $3.17, which is equal to the closing price of Gritstone’s common stock on April 21, 2022, the grant date of the awards.
-
Gritstone Presentations at AACR Further Support Expertise in Neoantigen Vaccine Design and Delivery
4/12/2022
Gritstone bio, Inc. delivered three presentations further supporting the potential of its novel vaccine development capabilities and delivery platforms to develop transformational therapeutic cancer vaccines at the 2022 American Association for Cancer Research Annual Meeting.
-
Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
4/7/2022
Onxeo S.A., hereafter “Onxeo” or the “Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response, announced the appointment of Dr. Shefali Agarwal as President and Chief Executive Officer.
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 30, 2022
3/30/2022
Gritstone bio, Inc. announced that the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 14,800 shares of its common stock with an exercise price of $4.90, which is equal to the closing price of Gritstone’s common stock on March 17, 2022, the grant date of the awards.
-
Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors
3/15/2022
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Steve Krognes will transition from his role as Chief Financial Officer (CFO) and join the company’s Board of Directors on May 1, 2022.
-
Gritstone Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Corporate Updates
3/10/2022
Gritstone bio, Inc., a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent clinical and corporate updates.
-
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
-
Gritstone Announces Three Presentations for Tumor-Specific Neoantigen (TSNA) Oncology Programs, GRANITE and SLATE, at the 2022 AACR Annual Meeting
3/8/2022
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, in New Orleans, Louisiana.
-
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
2/24/2022
Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer will participate in the “Infectious Disease” panel at the Cowen 42nd Annual Health Care Conference, which is being held virtually from March 7 to 9.
-
Prescription drug costs have continued to rise, with more than 150 drug manufacturers raising their prices in January.
-
Gritstone to Participate in Precision Oncology Panel at BIO CEO & Investor Conference
2/8/2022
Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will participate in a panel discussion on the role and future of precision oncology at the 2022 BIO CEO & Investor Conference, taking place at the Marriott Marquis in New York City from February 14 to 15 and virtually through February 17, 2022.
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 08, 2022
2/8/2022
Gritstone bio, Inc. announced that the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 35,400 shares of its common stock with an exercise price of $5.46, which is equal to the closing price of Gritstone’s common stock on January 31, 2022, the grant date of the awards.
-
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 25, 2022
1/25/2022
Gritstone bio, Inc. announced that the company’s Board of Directors has granted eleven employees nonqualified stock options to purchase an aggregate of 63,400 shares of its common stock with an exercise price of $6.30, which is equal to the closing price of Gritstone’s common stock on January 13, 2022, the grant date of the awards.
-
Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.
-
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
1/13/2022
Gritstone bio, Inc. today announced that the first patient has been enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial.